Alzamend Neuro™ has licensed the USF treatment to help advance commercialization
TAMPA, Fla. – A neuroscientist at the USF Health Byrd Alzheimer’s Institute and the USF College of Pharmacy has developed an immunotherapeutic treatment now undergoing testing for the prevention, treatment and cure of Alzheimer’s disease as well as other neurological disorders. This innovative technology has been exclusively licensed from USF to Alzamend Neuro™, Inc. Chuanhai Cao, a USF associate professor of pharmaceutical sciences and a researcher at the USF Health Byrd Alzheimer’s Institute, has focused his research on peptides for use as a vaccine for Alzheimer’s disease and other neurological diseases. Dr. Cao has developed an antigen activated immune cell-based vaccine that shows promise in helping combat nervous system dysfunctions in Alzheimer’s disease. Research has shown that the therapeutic vaccine can target the toxic protein in the brain and fix the impaired immune system in several Alzheimer’s mouse models. “Our research team has developed a therapeutic vaccine that can both combat the disease and improve the immune system,” Cao said. “The most recent results have proved that such therapy can improve memory and avoid an unwanted vaccine associated reaction in a mouse model, so it could be a very promising therapeutic for Alzheimer’s disease patients.” FULL ARTICLE
About Alzamend Neuro, Inc.
What is Alzheimer's disease?
Alzamend Neuro is currently working to move a patented mutant peptide for use as an immunotherapeutic treatment and vaccine out of the research and pre-clinical stage at the University of South Florida Byrd Institute and into a path toward commercialization.
Alzamend Neuro has been qualified by the SEC to raise $50 Million dollars under the new Regulation A+ which was signed into Law by President Obama as part of the Jobs Act of 2012 Alzamend Neuro is the first BIo-Tech company to receive this qualification.
We invest in innovation.
Through the Licensing of promising intellectual property from internationally recognized organizations, moving it forward toward commercialization and the support of ongoing research Alzamend Neuro, has and will continue to strive help move the battle against Alzheimer's forward.
As of December 8th, 2016 Alzamend Neuro is the first Bio-Tech company to receive a qualification of its Reg. A+ Tier II Offering, by the SEC, to raise up to $50 Million dollars. These new rules, which went into effect in June 2015, allow all types (accredited, non-accredited but qualified, institutional and international) investors to participate in what is commonly referred to as a Mini-IPO.
About Alzamend Neuro, Inc.
Alzamend Neuro is currently working to move a patented mutant peptide for use as an immunotherapeutic treatment and vaccine out of the research and preclinical stage at the University of South Florida Byrd Institute and into a path toward commercialization.
Alzamend Neuro has been qualified by the SEC to raise $50 Million dollars under the new Regulation A+ which was signed into Law by President Obama as part of the Jobs Act of 2012 Alzamend Neuro is the first Life Sciences company to receive this qualification.